Today's Breaking News
- Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility
- Biogen Idec Submits Application to FDA for Approval of PLEGRIDY (Peginterferon Beta-1a) in Multiple Sclerosis
- Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
Latest R&D and Business News
- Intercell Announces Pediatric Approval of its Japanese Encephalitis Vaccine in the U.S.
- Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin
- Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013
- Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
- 4SC's partner Yakult Honsha starts clinical Phase I/II study with cancer compound resminostat in liver cancer (HCC) in Japan
- Medivir: Positive results from a phase Ia study with MIV-711 for the treatment of skeletal disorders
- Oncopeptides Secures Venture Funding for Phase II Trial of Melflufen in Multiple Myeloma Patients
- Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
- Synergy Pharmaceuticals Presents Plecanatide Results From a Large Multicenter Clinical Study at Late-Breaking Abstract Session During Digestive Disease Week 2013
- Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441
- MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
- ChemoCentryx Announces Phase I Data With CCX507, Company's New Generation Orally Administered CCR9 Inhibitor